Emcure Pharmaceuticals has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations facility in Sanand, Ahmedabad. The USFDA has classified the inspection status as Voluntary Action Indicated (VAI), signifying the closure of the inspection with no significant compliance issues noted. This update follows an earlier intimation regarding the inspection conducted from May 06 to May 15, 2026.
USFDA Inspection Concluded at Sanand Facility
Emcure Pharmaceuticals Limited announced on August 8, 2026, that it has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) concerning its formulations manufacturing facility located at G.I.D.C., Taluka – Sanand, Ahmedabad, Gujarat. This facility was previously inspected by the USFDA from May 06, 2026, to May 15, 2026.
Voluntary Action Indicated (VAI) Classification
The company has been informed that the USFDA has classified the outcome of this inspection as Voluntary Action Indicated (VAI). This classification indicates that while observations may have been made, they do not rise to the level of Official Action Indicated (OAI) and are considered manageable by the company. Consequently, the inspection process for this facility has been formally closed.
Impact and Next Steps
The VAI classification is generally viewed positively by the industry, as it suggests that the facility’s operations are in compliance with the core requirements of the US FDA. This outcome is crucial for Emcure’s ability to continue supplying products to the U.S. market from its Sanand site. The company has requested that this information be taken on record by the stock exchanges.
Source: BSE
